Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. John Mascarenhas is associate professor of medicine at the Icahn School of Medicine at Mount Sinai. He is an active member of the Tisch Cancer Institute and a dedicated clinical investigator in myeloproliferative neoplasms. Dr. Mascarenhas has a large clinical practice of myeloid malignancies and is specifically interested in the development of novel therapies for patients with polycythemia vera, essential thrombocythemia, myelofibrosis and forms of acute myeloid leukemia. He is the Principal Investigator of over a dozen clinical trials including Phase I, II and III trials. He also serves as the Principal Investigator of the clinical trials arm of the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium.Dr. Mascarenhas serves on clinical trials steering committee for Incyte and on a DSMB for Novartis. Clinical trial funding is paid to the institution from Incyte, Novartis, Roche, Promedior, Janssen and CTI Biopharma.